| Filed On | Filing |
|---|---|
| 18 Sep 2026 |
8-K: Results of Operations and Financial Condition
Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
45% objective response rate and 88% disease control rate observed in patients with |
| 10 Aug 2026 | 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events |
Loading...
